Skip to main content
Professional Technical IVT

molecular subtyping

Classification of breast cancers based on gene expression patterns that define biologically distinct tumor types with different treatment implications.

Full Definition

Molecular subtyping is a classification system that categorizes breast cancers into distinct subtypes based on their molecular characteristics, particularly gene expression profiles. The primary subtypes include luminal A, luminal B, HER2-enriched, and basal-like tumors. This classification is typically approximated in clinical practice using immunohistochemical markers for estrogen receptor, progesterone receptor, HER2, and Ki-67. Molecular subtyping provides valuable information about tumor biology, prognosis, and treatment response patterns. It helps guide therapeutic decisions by identifying tumors likely to respond to specific targeted therapies and predicting sensitivity to chemotherapy and endocrine therapy. Advanced molecular assays like PAM50 can provide more precise subtype classification than immunohistochemistry alone.

Usage

Usage note: Distinguish from simple receptor status testing; molecular subtyping encompasses broader biological characterization.

In Context

  • "Molecular subtyping revealed a luminal B tumor requiring both endocrine and chemotherapy." — Treatment planning document
  • "The PAM50 assay provided definitive molecular subtyping for this borderline case." — Laboratory report

Also known as

intrinsic subtyping breast cancer molecular classification

Don't confuse with

histological grading staging receptor status

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON